Drug has only been tested in mice.

Of course, in this case the issue seems like it's caused by a general deficiency of single protein, maybe that's a good sign for adapting the treatment to humans.

undefined

Very strange how HN elevates news about random drug candidates at very early stages of development.

There is a very active landscape of people developing/validating 'biomarkers' for neurological and psychiatric disorders and developing drugs specifically for those populations with the biomarker present; this news is far from extraordinary.

The real news is when these reach FDA approval.

It's been awhile since I read about this stuff...is schizophrenia a spectrum disorder like autism? If so, I wonder if there's a point on the spectrum where it's not worth treating it because of possible side effects.

I feel like our society over-pathologizes a lot of stuff and it would be a shame if we "cured" something that doesn't need a cure.

That would be an incredible cure and raises the ethical question of how to get schizophrenic people well enough to understand that they need it.

I find this very suspect that a biomarker for schizophrenia is found before "black" gene/biomarker is found. It sounds like a setup for mass gaslighting and institutionalization by big pharma. Society is always looking for an easy way to institutionalize people it doesn't agree with. This is the big tech version.

Interesting... too bad it requires a spinal tap, not a super fun test to get.